The UK medicines regulator has said benefits of the Oxford/AstraZeneca vaccine continue to outweigh any risks, but added that under-30s will be offered an alternative jab.
Here, we take a look at the key questions surrounding the situation.
The UK medicines regulator has said benefits of the Oxford/AstraZeneca vaccine continue to outweigh any risks, but added that under-30s will be offered an alternative jab.
Here, we take a look at the key questions surrounding the situation.
A new side effect, VITT, linked to AstraZeneca's COVID vaccine, has emerged alongside concerns about Thrombotic Thrombocytopenia..
These are the key stories from the Brussels bubble this week.